ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on X

Kidney Week

Abstract: FR-PO156

DNase-1 Exerts Protective Effects after Severe Kidney Ischemia-Reperfusion Injury

Session Information

  • AKI: Mechanisms
    October 25, 2024 | Location: Exhibit Hall, Convention Center
    Abstract Time: 10:00 AM - 12:00 PM

Category: Acute Kidney Injury

  • 103 AKI: Mechanisms

Authors

  • Tutunea-Fatan, Elena, Western University, London, Ontario, Canada
  • Arumugarajah, Shabitha, Western University, London, Ontario, Canada
  • Gunaratnam, Lakshman, Western University, London, Ontario, Canada
Background

Kidney Injury Molecule-1 (KIM-1) is a transmembrane receptor expressed by proximal tubular epithelial cells during injury. KIM-1 recognizes phosphatidylserine, an “eat me” signal that marks apoptotic cells for phagocytic clearance. Notwithstanding that, severe acute injury (AKI) leads to persistent KIM-1 expression and drives fibrosis. Herein, we design a study to evaluate whether DNase1 contribute to the pathogenesis of KIM-1- mediated renal fibrosis.

Methods

To assess the functional role of KIM-1 expression, KIM-1+/+, KIM-1-/-, and Tim1fl/fl SLC34a1 C57BL/6 mice were subjected to both moderate (25 minutes) and severe (45 minutes) unilateral ischemia reperfusion injury (UIRI). Kidneys were isolated after 3, 7, 28, and 42 days of reperfusion to assess histology and markers of injury and fibrosis. To examine gene expression profile, RNA sequencing of kidneys from KIM-1+/+ and KIM-1-/- mice after 45 min UIRI was performed. DNase1 expression and activity was assessed by using in situ and in vitro analyses of kidneys and sera. To test the therapeutic potential of DNase1 after severe UIRI, mice received repeated doses of DNase1 (2 mg/kg) or vehicle-solution (NaCl 0.9%).

Results

Our data indicate that by clamping the renal pedicle for 45 min and following the mice for 42 days, the injured KIM-1+/+ kidneys were markedly reduced in size and fibrotic compared with control kidneys. By contrast, the injured KIM-1-/- kidney recovered completely. The fibrotic phenotype was not observed with the moderate injury model. Also, a strong upregulation of mRNA encoding a panel of cytokines and growth factors was observed at both 7 and 42 days after injury in KIM-1+/+ kidney compared with KIM-1-/-. This highlights the possibility that KIM-1 might directly regulate epithelial cytokine and fibrotic marker expression. In addition, DNase1 was among the top downregulated genes in the KIM-1+/+ kidney exposed to severe injury. Renal DNase1 expression was completely abrogated in KIM-1+/+ kidney compared to KIM-1-/- kidney at all time points analysed. Early decline of DNase1 activity directly correlated with lower injury score and fibrosis. DNase-1 treatment significantly reduced the pro-inflammatory response and histopathological changes observed in KIM-1+/+ kidney after severe AKI.

Conclusion

DNase1 therapy is protective following severe AKI and attenuates murine kidney fibrosis.

Funding

  • Government Support – Non-U.S.